script.reportAU
Register
← The record

LosartanCozaar

Recommended CardiovascularUnrestricted

treatment of hypertension

1
Submissions
2010–10
On the record
—
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Jul 2010 Recommended Antihypertensive

Access path

1 submission · public record
  1. TGA registered · Cozaar

    TGA label narrower than the PBS population

  2. Jul 2010
    Recommended

    vs irbesartan

  3. PBS listing · Unrestricted
RecommendedDeferredNot recommended

Cost-effectiveness

Cost-minimisation analysis: no ICER calculated by design

The PBAC noted that in the optional titration trials, two of the three comparisons (Dang 2006, Fogari 2001) show no statistically significant differences between treatments in diastolic blood pressure (DBP), and one (Oparil 1998) showed a statistically significant difference, with irbesartan producing larger reduction in diastolic blood pressure than losartan. However, there was no statistically significant difference in systolic blood pressure (SBP) in any of these three trials. PBAC · 2010
Surrogate endpoint

Decision context

Populationpatients with hypertension

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Jul 2010 Recommended irbesartan — RCT · Other

Similar precedents

By decision profile
Olmesartan Medoxomil79%Olmesartan Medoxomil With Hydrochlorothiazide69%Valsartan With Hydrochlorothiazide68%Olmesartan Medoxomil With Amlodipine68%Amlodipine Besylate With Valsartan67%Lercanidipine With Enalapril65%Telmisartan With Amlodipine65%Trandolapril With Verapamil Hydrochloride-Sr64%

Regulatory · TGA

Label narrower than PBS population — PBAC recommends general hypertension treatment; TGA label includes additional indication for hypertensive type 2 diabetics with proteinuria.

Product Information ↗ ARTG search ↗